Walter Bordogna

3.9k total citations · 4 hit papers
49 papers, 2.6k citations indexed

About

Walter Bordogna is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Walter Bordogna has authored 49 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Walter Bordogna's work include Lung Cancer Treatments and Mutations (43 papers), Lung Cancer Research Studies (23 papers) and Cancer Genomics and Diagnostics (15 papers). Walter Bordogna is often cited by papers focused on Lung Cancer Treatments and Mutations (43 papers), Lung Cancer Research Studies (23 papers) and Cancer Genomics and Diagnostics (15 papers). Walter Bordogna collaborates with scholars based in Switzerland, United States and France. Walter Bordogna's co-authors include Bogdana Balas, Shirish M. Gadgeel, D. Ross Camidge, Sai‐Hong Ignatius Ou, Alice T. Shaw, Ali Zeaiter, Jin Seok Ahn, Rafał Dziadziuszko, Tarek Mekhail and Johannes Noé and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Walter Bordogna

48 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

2015 462 citations Alice T. Shaw, Leena Gandhi et al. The Lancet Oncology profile →
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

2015 430 citations Sai‐Hong Ignatius Ou, Jin Seok Ahn et al. Journal of Clinical Oncology profile →
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

2020 414 citations Tony Mok, D. Ross Camidge et al. Annals of Oncology profile →
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

2019 319 citations D. Ross Camidge, Rafał Dziadziuszko et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by Walter Bordogna

Since Specialization

Citations

This map shows the geographic impact of Walter Bordogna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Walter Bordogna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Walter Bordogna more than expected).

Fields of papers citing papers by Walter Bordogna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Walter Bordogna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Walter Bordogna. The network helps show where Walter Bordogna may publish in the future.

Co-authorship network of co-authors of Walter Bordogna

This figure shows the co-authorship network connecting the top 25 collaborators of Walter Bordogna. A scholar is included among the top collaborators of Walter Bordogna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Walter Bordogna. Walter Bordogna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion–Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting 2024 ·JCO Precision Oncology ·Allan Hackshaw, Otto Fajardo, Urania Dafni, Hans Gelderblom, Pilar Garrido, Salvatore Siena, Matthew H. Taylor, Walter Bordogna, Christos Nikolaidis	0
2	Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer 2023 ·Lung Cancer ·Byoung Chul Cho, Chao‐Hua Chiu, Erminia Massarelli, Gary L. Buchschacher, Kōichi Goto, Tobias R. Overbeck, Herbert H. Loong, Cheng Ean Chee, Pilar Garrido, Xiaorong Dong, Yun Fan, Shun Lü, Sven Schwemmers, Walter Bordogna, Harald Zeuner, Stuart Osborne, Thomas John	19
3	Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC 2022 ·JTO Clinical and Research Reports ·Johannes Noé, Walter Bordogna, Venice Archer, Vlatka Smoljanović, Magalie Hilton, (unknown), Simonetta Mocci, Shirish M. Gadgeel	5
4	Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study breakdown → 2020 ·Annals of Oncology ·Tony Mok, D. Ross Camidge, Shirish M. Gadgeel, Rafael Rosell, Rafał Dziadziuszko, D.-W. Kim, M. Pérol, S.-H.I. Ou, Jin Seok Ahn, A. Shaw, Walter Bordogna, Vlatka Smoljanović, Magalie Hilton, Thorsten Ruf, Johannes Noé, Solange Peters	414
5	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer 2019 ·Lung Cancer ·Sai‐Hong Ignatius Ou, Shirish M. Gadgeel, Fabrice Barlési, James Chih‐Hsin Yang, Luigi De Petris, Dong‐Wan Kim, Ramaswamy Govindan, Anne‐Marie C. Dingemans, Lucio Crinò, H. Léna, Sanjay Popat, Jin Seok Ahn, Éric Dansin, Emmanuel Mitry, (unknown), Walter Bordogna, Bogdana Balas, Peter N. Morcos, Alice T. Shaw	21
6	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study breakdown → 2019 ·Journal of Thoracic Oncology ·D. Ross Camidge, Rafał Dziadziuszko, Solange Peters, Tony Mok, Johannes Noé, Małgorzata Nowicka, Shirish M. Gadgeel, Parneet Cheema, Nick Pavlakis, Filippo de Marinis, Byoung Chul Cho, Li Zhang, Denis Moro‐Sibilot, Ting Liu, Walter Bordogna, Bogdana Balas, Bárbara Müller, Alice T. Shaw	319
7	ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials 2019 ·Journal of Thoracic Oncology ·Johannes Noé, Alex Lovejoy, Sai‐Hong Ignatius Ou, Stephanie J. Yaung, Walter Bordogna, Daniel M. Klass, Craig Cummings, Alice T. Shaw	40
8	Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer 2018 ·Cancer Chemotherapy and Pharmacology ·Peter N. Morcos, (unknown), (unknown), Elena Guerini, Joy Hsu, Walter Bordogna, Bogdana Balas, François Mercier	24
9	Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer 2018 ·ESMO Open ·Sai‐Hong Ignatius Ou, Mark A. Socinski, Shirish M. Gadgeel, Leena Gandhi, Howard West, Alberto Chiappori, Victor Cohen, Gregory J. Riely, Vlatka Smoljanović, Walter Bordogna, (unknown), Kendra DeBusk, Ali Zeaiter, Alice T. Shaw	6
10	MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer 2017 ·Journal of Thoracic Oncology ·D. Ross Camidge, Shirish M. Gadgeel, (unknown), Leena Gandhi, Gregory J. Riely, Jeremy Cetnar, Howard West, Mark A. Socinski, Alberto Chiappori, Tarek Mekhail, Bo H. Chao, Hossein Borghaei, Kathryn A. Gold, Walter Bordogna, Bogdana Balas, Johannes Noé, Sophie Golding, Ali Zeaiter, Alice T. Shaw	10
11	Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer 2017 ·Journal of Thoracic Oncology ·James Chih‐Hsin Yang, Sai‐Hong Ignatius Ou, Luigi De Petris, Shirish M. Gadgeel, Leena Gandhi, Dong‐Wan Kim, Fabrice Barlési, Ramaswamy Govindan, Anne‐Marie C. Dingemans, Lucio Crinò, H. Léna, Sanjay Popat, Jin Seok Ahn, Éric Dansin, Sophie Golding, Walter Bordogna, Bogdana Balas, Peter N. Morcos, Ali Zeaiter, Alice T. Shaw	65
12	Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies 2017 ·Cancer Chemotherapy and Pharmacology ·Peter N. Morcos, Katrijn Bogman, Stanislas Hubeaux, (unknown), Thorsten Ruf, Walter Bordogna, Sophie Golding, Ali Zeaiter, Markus Abt, Bogdana Balas	33
13	Retrospective indirect comparison of alectinib phase II data vs ceritinib real-world data in ALK+ NSCLC after progression on crizotinib 2017 ·Annals of Oncology ·(unknown), (unknown), Reynaldo Martina, Paul Delmar, Mathieu Coudert, Walter Bordogna, S Golding, Gracy Crane	3
14	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK -positive non–small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria 2017 ·European Journal of Cancer ·Leena Gandhi, Sai‐Hong Ignatius Ou, Alice T. Shaw, Fabrice Barlési, Anne‐Marie C. Dingemans, Dong‐Wan Kim, D. Ross Camidge, Brett Hughes, James Chih‐Hsin Yang, Javier de Castro, Lucio Crinò, H. Léna, Pascal Dô, Sophie Golding, Walter Bordogna, Ali Zeaiter, (unknown), Shirish M. Gadgeel	24
15	Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC) 2016 ·Annals of Oncology ·Fabrice Barlési, Anne‐Marie C. Dingemans, James Chih‐Hsin Yang, (unknown), (unknown), Luigi De Petris, Benjamin Hughes, H. Léna, Walter Bordogna, S Golding, Peter N. Morcos, Bogdan Balas, Ali Zeaiter, Dongwook Kim	11
16	Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation 2016 ·Cancer Chemotherapy and Pharmacology ·Yasushi Yoshimura, Mitsue Kurasawa, Keigo Yorozu, Óscar Puig, Walter Bordogna, Naoki Harada	20
17	PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer 2015 ·Journal of Thoracic Oncology ·Denis Soulières, Fred R. Hirsch, Frances A. Shepherd, Walter Bordogna, Paul Delmar, David S. Shames, Barbara Klughammer	18
18	Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial breakdown → 2015 ·The Lancet Oncology ·Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel, Gregory J. Riely, Jeremy Cetnar, Howard West, D. Ross Camidge, Mark A. Socinski, Alberto Chiappori, Tarek Mekhail, Bo H. Chao, Hossein Borghaei, Kathryn A. Gold, Ali Zeaiter, Walter Bordogna, Bogdana Balas, Óscar Puig, Volkmar Henschel, Sai‐Hong Ignatius Ou	462
19	Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study breakdown → 2015 ·Journal of Clinical Oncology ·Sai‐Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, Ramaswamy Govindan, James Chih‐Hsin Yang, Brett Hughes, H. Léna, Denis Moro‐Sibilot, Alessandra Bearz, Santiago Viteri, Tarek Mekhail, Alexander I. Spira, Walter Bordogna, Bogdana Balas, Peter N. Morcos, Annabelle Monnet, Ali Zeaiter, Dong‐Wan Kim	430
20	Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial 2014 ·PLoS ONE ·Susana Benlloch, María Luisa Botero, (unknown), Clara Mayo, Ana Giménez‐Capitán, Itziar de Aguirre, Cristina Queralt, José Luis Ramírez, Santiago Ramón y Cajal, Barbara Klughammer, (unknown), Walter Bordogna, David Chen, Guili Zhang, (unknown), Felice Shieh, John F. Palma, Lin Wu, H. Jeffrey Lawrence, Miquel Tarón	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact